ARCA biopharma, Inc. Stock price

Equities

ABIO

US00211Y5069

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 03:19:56 2024-02-23 pm EST 5-day change 1st Jan Change
1.63 USD 0.00% Intraday chart for ARCA biopharma, Inc. -3.59% -5.29%
Sales 2022 - Sales 2023 - Capitalization 24.5M
Net income 2022 -9M Net income 2023 -5M EV / Sales 2022 -
Net cash position 2022 42.06M Net cash position 2023 37.15M EV / Sales 2023 -
P/E ratio 2022
-3.44 x
P/E ratio 2023
-4.59 x
Employees 5
Yield 2022 *
-
Yield 2023
-
Free-Float 98.08%
More Fundamentals * Assessed data
Dynamic Chart
1 week-3.59%
Current month+1.26%
1 month+1.90%
3 months-17.44%
6 months-21.46%
Current year-5.29%
More quotes
1 week
1.57
Extreme 1.57
1.67
1 month
1.57
Extreme 1.57
1.75
Current year
1.56
Extreme 1.56
1.75
1 year
1.56
Extreme 1.56
2.27
3 years
1.56
Extreme 1.56
4.87
5 years
1.56
Extreme 1.56
22.00
10 years
1.56
Extreme 1.56
299.88
More quotes
Managers TitleAgeSince
Founder 79 91-12-31
Director of Finance/CFO 60 21-05-09
Chief Operating Officer 65 06-09-30
Members of the board TitleAgeSince
Director/Board Member 58 17-02-15
Chairman 70 13-09-02
Founder 79 91-12-31
More insiders
Date Price Change Volume
24-02-23 1.61 -1.23% 4 010
24-02-22 1.63 +0.20% 12,084
24-02-21 1.627 -0.81% 64,675
24-02-20 1.64 -1.80% 12,414
24-02-16 1.67 +1.21% 16,732

Delayed Quote Nasdaq, February 23, 2024 at 01:26 pm EST

More quotes
ARCA biopharma, Inc. is a clinical stage biopharmaceutical company engaged in the development and commercialization of targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF), in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that the Company is developing for the treatment of AF in patients with heart failure. The Company's Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. The rNAPc2 is in a phase IIb clinical trial as a potential treatment for patients hospitalized with COVID-19.
More about the company
1st Jan change Capi.
-5.29% 24 M $
+5.67% 110 B $
+11.24% 104 B $
+9.93% 23 902 M $
-10.92% 22 243 M $
-26.36% 21 573 M $
-6.59% 18 925 M $
-14.30% 16 036 M $
+1.15% 13 271 M $
+41.42% 12 608 M $
Bio Therapeutic Drugs
  1. Stock
  2. Equities
  3. Stock ARCA biopharma, Inc. - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer